Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide Analogues

11 listopada 2026 zaktualizowane przez: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.

A Randomized, Double-blind, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of YKYY013 in Patients With HBeAg-negative Chronic Hepatitis B Virus Infection Treated With Nucleos(t)Ide Analogs

To evaluate the efficacy of YKYY013 in patients with chronic hepatitis B virus (HBV) infection with negative hepatitis B e antigen (HBeAg) and treated with nucleoside (acid) analogs (NA).

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Szczegółowy opis

1)Evaluate the safety and tolerability of YKYY013 in patients with HBeAg-negative chronic HBV infection treated with NA; 2) Evaluate the pharmacokinetic (PK,with the serum drug concentration of YKYY013) and pharmacodynamic (PD,with reduction in HBsAg) characteristics of YKYY013 in patients with HBeAg-negative chronic HBV infection treated with NA; 3) Evaluate the immunogenicity of YKYY013 in patients with HBeAg-negative chronic HBV infection treated with NA.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

120

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • Beijing Municipality
      • Beijing, Beijing Municipality, Chiny, 100050
        • Beijing Friendship Hospital, affiliated with Capital Medical University
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 65 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Body Mass Index (BMI) between 18.0 to 32.0 kg/m^2 (inclusive) and body weight equal to or over 50 kg for male and 45 kg for female.
  2. Chronic HBV infection , with positive hepatitis B surface antigen (HBsAg) or HBV DNA for at least 6 months, and continuous stable treatment with a single nucleoside (acid) analogue (NA) for ≥ 6 months.

3)HBeAg-negative at screening; 4)100 IU/mL < HBsAg ≤ 5000 IU/mL at screening; 5)HBV DNA < 100 IU/mL at screening. 6) Medically approved contraception (e.g., intrauterine device, oral contraceptive, condom) during the trial and for 6 months after the last dose, Participants must not donate sperm or ova during the trial or for 6 months after the last dose.

7) The participants voluntarily participate in the study, and sign the Informed Consent Form (ICF) prior to screening.

Exclusion Criteria:

  1. Severe allergic reactions, non-allergic drug reactions, multiple drug allergies, or known hypersensitivity to the investigational drug or its excipients.

  2. Chronic liver disease other than chronic HBV infection (e.g., severe fatty liver, alcoholic, autoimmune, or inherited metabolic liver disease).

  3. Liver stiffness measurement (LSM) above 9 kPa at screening, or Metavir F3 or higher on biopsy within 1 year before screening.

  4. Current or past hepatic decompensation (e.g., esophagogastric variceal bleeding, ascites, hepatic encephalopathy).

  5. Liver cancer history, or imaging (ultrasound, MRI, CT) suggesting liver cancer, or alpha-fetoprotein (AFP) at least 50 ug/L.

  6. Cardiovascular events (e.g., stroke, transient ischemic attack, myocardial infarction, unstable angina, coronary bypass surgery, percutaneous coronary intervention, heart failure hospitalization) or clinically significant valvular heart disease. Other chronic diseases considered unsuitable by the investigator (e.g., respiratory, endocrine, immune, renal, hepatic, gastrointestinal, dermatologic, hematologic, neurologic).

  7. Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage) or bleeding tendency (e.g., recurrent gingival bleeding); cured disease without active or clinically significant bleeding may be enrolled at investigator discretion.

  8. Severe infection within 1 month, or infection symptoms within 7 days, before screening.

  9. Major illness or major surgery (excluding minor outpatient procedures) within 3 months before screening, or planned grade 3-4 surgery during the trial.

  10. Malignancy within 5 years, except cured resected in situ carcinoma (e.g., non-melanoma skin cancer).

  11. Clinically significant abnormalities on physical examination, vital signs, 12-lead electrocardiogram (ECG), or chest CT at screening.

  12. Uncontrolled blood pressure at screening (systolic at least 160 mmHg or diastolic at least 100 mmHg despite treatment).

  13. Fridericia-corrected QT interval (QTcF) at least 450 msec (male) or 470 msec (female); if the first ECG exceeds these limits, two more ECGs are done and the mean of three applies.

  14. Significant laboratory abnormalities at screening, including:

    1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) at least 2 times the upper limit of normal (ULN).
    2. Total bilirubin at least 2 times ULN with direct bilirubin above ULN.
    3. Serum albumin below 35 g/L.
    4. Platelets below 100 x 10^9/L.
    5. Prothrombin time (PT) prolonged by more than 3 seconds, international normalized ratio (INR) above 1.3, or clinically significant fibrinogen abnormality.
    6. Creatinine clearance (Cockcroft-Gault) 60 mL/min or less, or clinically significant proteinuria.
    7. Poorly controlled diabetes with glycated hemoglobin (HbA1c) above 7.0%.
  15. AIDS, hepatitis A, B, C, or D, or positive screening for HIV antibody, Treponema pallidum antibody, or hepatitis A, B, C, or D antibody; positive hepatitis C antibody requires HCV RNA testing, and positive HCV RNA excludes.

  16. Any potentially hepatotoxic drug (prescription, over-the-counter, or herbal) within 14 days (or 5 half-lives, if longer) before the first dose, if judged unsuitable by the investigator; stable therapy for hypertension or diabetes is allowed.

  17. Interferon or immunosuppressant treatment within 12 months before screening, excluding short-term (2 weeks or less) use and topical or inhaled corticosteroids.

  18. Live vaccine within 1 month before screening.

  19. Small interfering RNA (siRNA) drug trial within 6 months, or other investigational drug within 3 months, before screening; or planned participation in another interventional trial.

  20. Severe intolerance to subcutaneous injection (mild local reactions are acceptable).

  21. Difficult venous access or venipuncture intolerance; history of syncope or hematophobia.

  22. Pregnancy, lactation, or positive pregnancy test at screening or baseline.

  23. Any scientific, compliance, or safety reason for which the investigator considers participation unsuitable.

  24. Inability to communicate or cooperate due to neurologic or psychiatric disorder or language barrier.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: YKYY013

Drug: YKYY013 Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

Drug: YKYY013 Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

Komparator placebo: YKYY013 Placebo

Drug: 0.9% Sodium Chloride Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

Drug: 0.9% Sodium Chloride Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Ramy czasowe
The proportion (percent) of participants who achieved serum HBsAg < LLOQ (0.05 IU/mL) and HBVDNA < LLOQ at the 24th week
Ramy czasowe: Week 24
Week 24

Miary wyników drugorzędnych

Miara wyniku
Ramy czasowe
The proportion (percent) of trial participants who maintained sustained efficacy during the 24-week period after discontinuation of YKYY013 (the NA monotherapy period, up to W72) after completing the YKYY013 treatment course.
Ramy czasowe: Week 72
Week 72
The proportion (percent) of participants who achieved serum HBsAg < LLOQ (0.05 IU/mL) and HBV DNA < LLOQ at the end of YKYY013 treatment.
Ramy czasowe: Week 48
Week 48
The proportion (percent) of trial participants who met the NA drug discontinuation criteria and stopped all chronic hepatitis B treatments (YKYY013 and NA drugs) and maintained sustained efficacy during a 24-week period.
Ramy czasowe: Week 72,Week 96
Week 72,Week 96
The proportion (percent) of trial participants who met the discontinuation criteria for NA treatment at the 72nd week
Ramy czasowe: Week 72
Week 72
Compared to the baseline level, the percentage (percent) of participants in the HBsAg test at different levels was reduced (e.g., ≥0.5, ≥1, ≥1.5, ≥2.0, ≥3 log10 IU/mL);
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The detection values (IU/mL) of HBsAg;
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The maximum reductions (IU/mL) of HBsAg from the baseline;
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The relative changes (IU/mL)of HBsAg from the baseline;
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The detection values (copies/ml) of HBV RNA;
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The maximum reductions (copies/ml) of HBV RNA from the baseline;
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The relative changes (copies/ml) of HBV RNA from the baseline;
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The detection values (U/mL) of HBcrAg;
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The maximum reductions (U/mL) of HBcrAg from the baseline;
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The relative changes (U/mL) of HBcrAg from the baseline;
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The detection values (IU/mL) of HBV DNA;
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The maximum reductions (IU/mL) of HBV DNA from the baseline;
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The relative changes (IU/mL) of HBV DNA from the baseline;
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The number and percentage (percent) of trial participants whose HBsAg and/or HBV DNA levels have dropped below the quantitative limit;
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The number and percentage (percent) of trial participants whose highly sensitive HBsAg (LLOQ ≤ 0.005 IU/mL) decreased below the quantitative limit;
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The positive rate (percent) and detection concentration (IU/L) of hepatitis B virus surface antibody (HBsAb);
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The positive rate (percent) of hepatitis B virus e antibody (HBeAb).
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
Adverse events during treatment (TEAE)
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
Number of participants with abnormally elevated body temperature.
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
Number of participants with reactions at the injection site from prior administration.
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
Number of participants with abnormal time between the start of the q wave and the end of the t wave (QT/QTc interval) on 12-lead electrocardiogram (ECG).
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
Number of participants with liver function abnormalities during the treatment period.
Ramy czasowe: From the first day to the 96th week
From the first day to the 96th week
The number and proportion of participants with positive anti-drug antibodies (ADA).
Ramy czasowe: Day 1, Day 169, Day 337, Day 505, Day 673, or Early Termination; sampling time windows consistent with visit windows; pre-dose on dosing days
Day 1, Day 169, Day 337, Day 505, Day 673, or Early Termination; sampling time windows consistent with visit windows; pre-dose on dosing days

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

30 października 2026

Zakończenie podstawowe (Szacowany)

20 marca 2027

Ukończenie studiów (Szacowany)

14 marca 2029

Daty rejestracji na studia

Pierwszy przesłany

21 października 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

11 listopada 2026

Pierwszy wysłany (Rzeczywisty)

12 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

12 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

11 listopada 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • CLSP-YKYY013-Z02

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .